In this new episode of the pharmaphorum podcast, host Nicole Raleigh speaks with James Burt, CEO of Pharmanovia, about the value-added medicines space.
The European Commission has pulled marketing authorisations for generic versions of Biogen’s oral multiple sclerosis therapy Tecfidera, after concluding that the brand qua
Among those celebrating today’s agreement on a voluntary rebate scheme for branded medicines in the UK, there are dissenting voices, including a group representing manufac
The financial regulator in the US has sent letters to 10 companies that it claims have improperly listed patents in the FDA’s ‘Orange Book’ in order to block generic rival
As the US and Europe experiences shortages of crucial medicines, Ben Hargreaves looks at how a once thriving generics industry is now struggling, with many companies seeking to exit the spa
The financial regulator in the US has warned the pharma industry that it may consider legal action against companies that improperly list patents in the FDA's 'Orange Book
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.